Press "esc" to clear
Go to Advanced Search
Showing results 20712080 of 2777

Article ID: 629196

Study Shows the Top Ten Global Health Pharmaceutical Supply Chain Issues

New York University

Global pharmaceutical supply chains are fragmented and lack coordination, facing at least 10 key challenges, according to the researchers. Their study sheds light on areas of weakness and what specifically is needed to strengthen the global health pharmaceutical supply chains.

Released:
3-Feb-2015 11:00 AM EST

Article ID: 629160

FDA Approves New Drug for Binge Eating Disorder (BED)

Obesity Society

The United States Food and Drug Administration (FDA) recently approved lisdexamfetamine dimesylate, under the brand name Vyvanse, to treat moderate to severe binge eating disorder (BED) in adults, a first of its kind prescription drug specifically indicated for BED. TOS says that understanding the differences between obesity and BED is important for clinicians, as BED is an eating disorder that affects only a portion of those with the medical disease obesity.

Released:
2-Feb-2015 3:00 PM EST
Fig.1G.ComplexofTSPOwithInhibitorPK11195.png
  • Embargo expired:
    29-Jan-2015 2:00 PM EST

Article ID: 628745

New Clues About a Brain Protein with High Affinity for Valium

Brookhaven National Laboratory

Valium, one of the best known antianxiety drugs, produces its calming effects by binding with a particular protein in the brain. But the drug has an almost equally strong affinity for a completely different protein. New studies revealing atomic level details of this secondary interaction might offer clues about Valium's side effects and point the way to more effective drugs.

Released:
25-Jan-2015 8:00 PM EST
  • Embargo expired:
    28-Jan-2015 4:00 PM EST

Article ID: 628599

Does Getting “Expensive” Drug Affect How Much Patient Benefits?

American Academy of Neurology (AAN)

People’s perceptions of the cost of a drug may affect how much they benefit from the drug, even when they are receiving only a placebo, according to a new study of people with Parkinson’s disease published in the January 28, 2015 online issue of Neurology®, the medical journal of the American Academy of Neurology.

Released:
21-Jan-2015 2:00 PM EST
  • Embargo expired:
    27-Jan-2015 2:00 AM EST

Article ID: 628779

Analysis Rejects Linkage Between Testosterone Therapy And Cardiovascular Risk

Beth Israel Deaconess Medical Center

Fears of a link between testosterone replacement therapy and cardiovascular risk are misplaced, according to a review published in this month’s Mayo Clinic Proceedings. The therapy has come under widespread scrutiny in recent months, including by a federal Food and Drug Administration (FDA) panel convened last fall.

Released:
26-Jan-2015 8:00 AM EST
CXCR4-chemokine-crystal-structure-USC.jpg

Article ID: 628697

Pictured Together for the First Time: A Chemokine and Its Receptor

University of California San Diego Health

Researchers at University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences and the Bridge Institute at the University of Southern California report the first crystal structure of the cellular receptor CXCR4 bound to an immune signaling protein called a chemokine. The structure answers longstanding questions about a molecular interaction that plays an important role in human development, immune responses, cancer metastasis and HIV infections.

Released:
22-Jan-2015 2:35 PM EST

Article ID: 628412

Century-Old Drug Reverses Autism-Like Symptoms in Fragile X Mouse Model

University of California San Diego Health

Researchers at UC San Diego School of Medicine previously reported that a drug used for almost a century to treat trypanosomiasis, or sleeping sickness, reversed environmental autism-like symptoms in mice. Now, a new study published in this week’s online issue of Molecular Autism, suggests that a genetic form of autism-like symptoms in mice are also corrected with the drug, even when treatment was started in young adult mice.

Released:
15-Jan-2015 3:00 PM EST
Roger_lo_2.jpg

Article ID: 628345

New Research Unlocks How Melanoma Can Resist Newly Approved Drug Combo Therapy

University of California, Los Angeles (UCLA), Health Sciences

In a new study researchers at the UCLA Jonsson Comprehensive Cancer Center have uncovered how melanoma becomes resistant to a promising new drug combo therapy utilizing BRAF+MEK inhibitors in patients after an initial period of tumor shrinkage.

Released:
15-Jan-2015 12:00 PM EST
Dr_2.Jian-DongLi
  • Embargo expired:
    14-Jan-2015 5:00 AM EST

Article ID: 628272

Researchers Discover New “Trick” Steroids Use To Suppress Inflammation

Georgia State University

A new “trick” steroids use to suppress inflammation, which could be used to make new anti-inflammatory drugs without the harmful side effects of steroids, has been discovered by researchers at Georgia State University.

Released:
13-Jan-2015 11:00 AM EST

Showing results 20712080 of 2777

Chat now!